Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Assets Average (2021 - 2025)

Historic Assets Average for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $686.7 million.

  • Kiniksa Pharmaceuticals International's Assets Average rose 2512.07% to $686.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $686.7 million, marking a year-over-year increase of 2512.07%. This contributed to the annual value of $553.4 million for FY2024, which is 1225.98% up from last year.
  • Kiniksa Pharmaceuticals International's Assets Average amounted to $686.7 million in Q3 2025, which was up 2512.07% from $630.2 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Assets Average peaked at $686.7 million during Q3 2025, and registered a low of $220.8 million during Q2 2022.
  • Moreover, its 5-year median value for Assets Average was $473.6 million (2023), whereas its average is $446.3 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Assets Average plummeted by 2520.89% in 2022 and then surged by 10999.05% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Assets Average (Quarter) stood at $242.8 million in 2021, then surged by 89.36% to $459.8 million in 2022, then rose by 9.76% to $504.7 million in 2023, then rose by 12.53% to $567.9 million in 2024, then increased by 20.92% to $686.7 million in 2025.
  • Its Assets Average stands at $686.7 million for Q3 2025, versus $630.2 million for Q2 2025 and $589.9 million for Q1 2025.